- Home
- ASRT vs SKYE Comparison
ASRT vs SKYE Comparison
Compare ASRT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- SKYE
- Stock Information
- Founded
- ASRT 1995
- SKYE 2012
- Country
- ASRT United States
- SKYE United States
- Employees
- ASRT N/A
- SKYE N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- SKYE Health Care
- Exchange
- ASRT Nasdaq
- SKYE Nasdaq
- Market Cap
- ASRT 79.1M
- SKYE 108.5M
- IPO Year
- ASRT 1997
- SKYE N/A
- Fundamental
- Price
- ASRT $0.97
- SKYE $3.94
- Analyst Decision
- ASRT Strong Buy
- SKYE Buy
- Analyst Count
- ASRT 1
- SKYE 7
- Target Price
- ASRT $3.00
- SKYE $15.50
- AVG Volume (30 Days)
- ASRT 283.1K
- SKYE 319.5K
- Earning Date
- ASRT 11-10-2025
- SKYE 11-06-2025
- Dividend Yield
- ASRT N/A
- SKYE N/A
- EPS Growth
- ASRT N/A
- SKYE N/A
- EPS
- ASRT N/A
- SKYE N/A
- Revenue
- ASRT $117,099,000.00
- SKYE N/A
- Revenue This Year
- ASRT N/A
- SKYE N/A
- Revenue Next Year
- ASRT $6.75
- SKYE N/A
- P/E Ratio
- ASRT N/A
- SKYE N/A
- Revenue Growth
- ASRT N/A
- SKYE N/A
- 52 Week Low
- ASRT $0.51
- SKYE $1.14
- 52 Week High
- ASRT $1.37
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- ASRT 78.53
- SKYE 54.83
- Support Level
- ASRT $0.79
- SKYE $3.71
- Resistance Level
- ASRT $0.83
- SKYE $4.55
- Average True Range (ATR)
- ASRT 0.04
- SKYE 0.32
- MACD
- ASRT 0.01
- SKYE 0.01
- Stochastic Oscillator
- ASRT 84.65
- SKYE 51.97
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.